Last updated: May 29, 2026

Application No. 18/004,287

METHOD FOR PRODUCING A MAMMALIAN BRAIN PROTEIN HYDROLYSATE

Non-Final OA

Filed

Jan 04, 2023

Priority

Jul 13, 2020 — EU 20185414.8 +1 more

Examiner

FONTAINHAS, AURORA M

Art Unit

1675

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Ever Neuro Pharma GmbH

OA Round

4 (Non-Final)

This examiner grants 38% of cases after interview

— +48.0% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 485 resolved cases, 2023–2026

Examiner Intelligence

FONTAINHAS, AURORA M View full profile →

Grants only 38% of cases

Career Allowance Rate

182 granted / 485 resolved

-22.5% vs TC avg

Strong +48% interview lift

Without

With

+48.0%

Interview Lift

resolved cases with interview

Typical timeline

3y 3m

Avg Prosecution

34 currently pending

Career history

535

Total Applications

across all art units

Statute-Specific Performance

§101

3.8%

-36.2% vs TC avg

§103

45.4%

+5.4% vs TC avg

§102

10.5%

-29.5% vs TC avg

§112

7.8%

-32.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 485 resolved cases

Prosecution Timeline

Show 5 earlier events

Jul 10, 2024

Request for Continued Examination

Jul 10, 2024

Response after Non-Final Action

Jul 16, 2024

Response after Non-Final Action

Jun 03, 2025

Non-Final Rejection mailed

Aug 05, 2025

Response Filed

Sep 04, 2025

Final Rejection mailed

Dec 29, 2025

Response after Non-Final Action

May 19, 2026

Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

17/784,127

Patent 12590147

TRPV1 EPITOPES AND ANTIBODIES

3y 9m to grant Granted Mar 31, 2026

17/016,860

Patent 12569572

MESSENGER RNA THERAPY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA

5y 6m to grant Granted Mar 10, 2026

17/209,125

Patent 12540949

Detection of Misfolded Alpha Synuclein Protein

4y 10m to grant Granted Feb 03, 2026

18/110,574

Patent 12534522

ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF

2y 11m to grant Granted Jan 27, 2026

17/730,074

Patent 12528858

Humanized Antibodies That Recognize Alpha-Synuclein

3y 9m to grant Granted Jan 20, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5

Expected OA Rounds

38%

Grant Probability

86%

With Interview (+48.0%)

3y 3m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 485 resolved cases by this examiner. Grant probability derived from career allowance rate.

METHOD FOR PRODUCING A MAMMALIAN BRAIN PROTEIN HYDROLYSATE

This examiner grants 38% of cases after interview

Examiner Intelligence

Statute-Specific Performance

Prosecution Timeline

Precedent Cases

Applications granted by this same examiner with similar technology

Strategy Recommendation AI-generated — please review before filing

Prosecution Projections

Ready to respond to this office action?

Sign in with your work email